Femasys Receives Approval From New Zealand's MEDSAFE For Its FemBloc Permanent Birth Control

Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) for its FemBloc Permanent Birth Control. This approval confirms that FemBloc meets the country's standards for safety, quality, and effectiveness, and represents an important milestone in Femasys' global expansion strategy to make this revolutionary non-surgical permanent birth control option available to women worldwide.

"MEDSAFE's regulatory approval of FemBloc permanent birth control represents another key step in broadening international market access to our innovative technology," said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. "Building on our recent CE Mark in Europe and approval in the UK, this accomplishment reflects growing regulatory confidence in our technology, and strengthens our focus on securing additional country approvals."